Global Pertussis Market Size To Exceed USD 7.04 Billion by 2035 | CAGR of 5.47%: Market Insight Report

• As per Spherical Insights & Consulting, The Global Pertussis Market Size is expected to Grow from USD 3.92 Billion in 2024 to USD 7.04 Billion by 2035, at a CAGR of 5.47% during the forecast period 2025-2035, owing to the launch of new therapies in the market and the rise in the number of cases.

 

• The leading Pertussis Companies such as Sanofi Pasteur, GlaxoSmithKline (GSK), Merck & Co., Inc., Pfizer Inc., CSL Limited (Seqirus), Serum Institute of India, Mitsubishi Tanabe Pharma, Walvax Biotechnology, Biological E. Limited, Bharat Biotech, Takeda Pharmaceutical, Sinovac Biotech, LG Chem, Emergent BioSolutions, Valneva SE, and Others.

 

• The Pertussis Market is projected To Grow with rising disease awareness and the development of more effective treatment and prevention options.

 

 

Pertussis Treatment Market: Understanding and Treatment Algorithm:

Pertussis, also known as whooping cough, is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It leads to severe coughing fits, often followed by a “whooping” sound during inhalation. Pertussis mainly affects infants and young children but can impact all ages. Vaccination remains the most effective method for prevention and control. Complications can include pneumonia, seizures, and even death in severe cases, especially in unvaccinated infants. Booster doses are recommended for adolescents and adults to maintain immunity and protect vulnerable populations through herd immunity.

 

Pertussis Diagnosis:

Pertussis diagnosis involves a combination of clinical assessment and laboratory tests. Common diagnostic methods include polymerase chain reaction (PCR) testing, which detects Bordetella pertussis DNA, and bacterial culture from a nasopharyngeal swab. Serology may be used in later stages. Early and accurate diagnosis is crucial to begin treatment, reduce transmission, and manage outbreaks effectively.

 

Pertussis Prevention and Treatment

Pertussis prevention primarily relies on vaccination, with DTaP for children and Tdap booster shots for adolescents and adults. Timely immunization helps protect vulnerable groups, especially infants. Treatment includes antibiotics like azithromycin or erythromycin, which reduce symptoms and transmission if started early. Supportive care is essential, particularly for severe cases, to manage coughing fits and complications.

 

Pertussis Epidemiology

The epidemiology section of the pertussis report offers an overview of both historical and current patient populations, along with forecasted trends across seven major countries. It examines underlying causes through various studies and expert insights, and includes data on diagnosed cases, associated trends, and the assumptions used in forecasting in the global market covering the North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa from 2024 to 2035.

 

Principal Insights

This section offers a global overview of pertussis epidemiology in major markets worldwide.

 

Country Wise- Pertussis Epidemiology

• The epidemiology segment provides pertussis prevalence data and findings across key regions worldwide, including North America, Europe (Germany, France, Italy, Spain, and the United Kingdom), Asia-Pacific (including Japan), Latin America, the Middle East, and Africa.

 

• According to the China CDC, 32,380 cases were reported in the first two months of 2024, which is nearly 23 times higher than the cases reported during the same period in 2023. However, the true incidence is likely underestimated due to misdiagnosis and inadequate surveillance systems.

 

• Data provided by CDC In 2024, pertussis cases reported across the United States saw a significant rise. Preliminary data indicate that the number of cases in 2024 was over six times higher than in 2023.

 

Pertussis Recent Developments

• In September 2020, Sanofi Pasteur India, the vaccines global business unit of Sanofi, announced the launch of Tetraxim® (DTaP-IPV). The booster vaccine was indicated for preschoolers and provided protection against four major diseases – diphtheria, pertussis, tetanus, and polio. Tetraxim® combined four vaccines into one, thus reducing the number of injections, increasing comfort, improving vaccination compliance for children, and reducing parental anxiety.

 

Pertussis Marketed Drugs:

• Infanrix: GlaxoSmithKline

Infanrix, is a combination vaccine that protects against diphtheria, tetanus, and pertussis (DTaP). It is commonly administered to infants and young children in a series of doses. Infanrix works by stimulating the immune system to build protection against these serious bacterial infections, significantly reducing disease incidence and enhancing community-wide immunity through vaccination programs.

 

• Kinrix: GlaxoSmithKline

Kinrix, is a combination vaccine designed to protect children against diphtheria, tetanus, pertussis (DTaP), and poliovirus (IPV). It is typically given as a booster dose to children aged 4–6 years. Kinrix simplifies immunization by reducing the number of injections, ensuring effective protection and improving compliance with recommended childhood vaccination schedules.

 

• DAPTACEL: Sanofi Pasteur

DAPTACEL, is a combination vaccine that protects against diphtheria, tetanus, and pertussis (DTaP). It is primarily administered to infants and young children in multiple doses. DAPTACEL helps the immune system build defense against these serious bacterial infections, playing a crucial role in childhood immunization programs worldwide.

 

Pertussis Emerging therapies

• Novel Approaches: Novel approaches in pertussis treatment focus on enhancing vaccine efficacy and developing new therapies to overcome antibiotic resistance. These include improved acellular vaccines, intranasal live attenuated vaccines, and immune-boosting adjuvants. Such innovations aim to provide longer-lasting protection and reduce disease transmission.

 

• In Development or Clinical Trials: Several pertussis treatments and vaccines are currently in development or clinical trials, including next-generation acellular vaccines, live attenuated intranasal vaccines, and novel adjuvants to boost immune response. These innovations aim to enhance long-term immunity, reduce bacterial colonization, and address waning protection from existing vaccines, marking a promising shift in pertussis management.

 

Pertussis Market Outlook

• The Pertussis Market involves the production and sale of vaccines and treatments for whooping cough, a contagious respiratory disease. It includes acellular and whole-cell vaccines, diagnostics, and related healthcare services, driven by vaccination programs, government support, and growing awareness to prevent pertussis infections globally.

 

• The increasing pertussis outbreaks, government vaccination programs, rising awareness about disease prevention, advancements in vaccine technology, growing infant and pediatric populations, and global efforts to reduce morbidity and mortality associated with whooping cough infections are market drivers.

 

• Growing demand for improved pertussis vaccines and increasing government funding for immunization programs present significant market opportunities. Additionally, expanding awareness in developing regions offers potential for market growth.

 

• Regulatory initiatives focus on ensuring vaccine safety and efficacy through stringent approval processes by agencies like the FDA and EMA. Governments also implement mandatory vaccination policies to control pertussis outbreaks and promote public health.

 

• The major challenge in the pertussis market is vaccine hesitancy, which leads to lower vaccination rates and increases the risk of disease outbreaks.

 

• Together, these factors collectively drive the growth and expansion of the pertussis market worldwide.

 

Pertussis Market Segmentation

 

 

The blood tests segment dominates the pertussis market with the largest share due to its rapid results, ease of administration, and ability to detect immune response even in later stages. Its widespread use in clinical and laboratory settings significantly boosts its market presence.

 

The vaccination segment dominates the pertussis market due to its effectiveness in disease prevention and inclusion in routine immunization programs. Acellular vaccines like DTaP and Tdap ensure widespread coverage, especially in children. This preventive approach significantly reduces infection rates, making vaccination the cornerstone of global pertussis control and management.

 

Pertussis Market Report Scope

• The pertussis therapeutics market report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
• Detailed insights into pertussis epidemiology and therapeutic approaches are included.
• Additionally, a comprehensive review of existing and emerging pertussis therapies is provided, including an evaluation of new treatments expected to influence the current glioblastoma treatment market landscape.
• The report includes a detailed review of the pertussis therapeutics market, both historical and forecasted, highlighting the global drug reach.
• The Patient-Based Pertussis Market Forecasting report offers valuable insights into trends shaping the global market, helping to develop effective business strategies.

 

Pertussis Market Report Insights

• Forecasting Market Trends Based on Patient Data and Disease Rates
• Pertussis Therapeutic Approaches in Pertussis
• Review Of Drugs in Development for Pertussis
• Market, Growth, and Trends in Pertussis
• Market Opportunities in Pertussis Treatment
• Effects Of Future Therapies on Pertussis Treatment

 

Pertussis Market Report Key Strengths

• 15 Years Pertussis Market Forecast
• Global Coverage
• Pertussis Epidemiology Segmentation
• Key Cross Competition

 

Pertussis Market Report Assessment

• Present Practices in the Pertussis Treatment Market
• Review of Investigational Pertussis Drugs
• Attractiveness of the Pertussis Drug Market
• Pertussis Market Drivers
• Pertussis Market Barriers
• SWOT
• Attribute Analysis